Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
What if the missing link in treating autoimmune disease wasn't a new drug—but a better way to measure stress?
In this episode of Med Tech Gurus, we sit down with Dr. Andrew Holman, CEO of Inmedix and the innovator behind CloudHRV, the first FDA-cleared platform to measure stress biology with medical-grade precision
.At a time when 75% of autoimmune treatments fail—costing billions and leaving patients without answers—CloudHRV delivers actionable insights in just five minutes reframing how clinicians think about chronic disease.
Dr. Holman takes us inside his two-decade journey building Inmedix, from early IP strategy to securing partnerships with global pharma. Along the way, he shares lessons on leveraging licensing as a growth strategy, building a culture of innovation, and aligning science, business, and patient care in the pursuit of transformative healthcare solutions.
Whether you're a founder, investor, or clinician, this conversation will reshape how you think about precision medicine and the future of patient-centered innovation.